MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Acquires 37,595 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 37,595 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $49,625.40. Following the purchase, the director directly owned 773,296 shares in the company, valued at approximately $1,020,750.72. The trade was a 5.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.35 per share, for a total transaction of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero acquired 8,931 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.39 per share, with a total value of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN:MAIA opened at $1.39 on Tuesday. The company’s 50-day moving average is $1.35 and its 200 day moving average is $1.39. The company has a market capitalization of $84.55 million, a P/E ratio of -2.24 and a beta of 0.25. MAIA Biotechnology, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, research analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors have recently bought and sold shares of the company. Centric Wealth Management bought a new position in MAIA Biotechnology during the second quarter valued at $1,107,000. Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology in the second quarter valued at $741,000. BlackRock Inc. purchased a new position in shares of MAIA Biotechnology during the 2nd quarter valued at $580,000. Susquehanna International Group LLP purchased a new position in shares of MAIA Biotechnology during the 2nd quarter valued at $51,000. Finally, PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology during the 1st quarter worth $46,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.